Abstract A84: Role of Akt pathway in the response of cetuximab in a resistant head and neck cell line
M Rebucci, P Peixoto, A De Witte, C Dewas… - Molecular Cancer …, 2009 - AACR
Abstract The Epidermal Growth Factor Receptor (EGFR) is a central regulator of cell
proliferation and differentiation in human cancers and is frequently overexpressed in many …
proliferation and differentiation in human cancers and is frequently overexpressed in many …
Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance
M Rebucci, P Peixoto, A Dewitte… - International …, 2011 - spandidos-publications.com
EGFR is frequently overexpressed in head and neck squamous cell cancer (HNSCC).
Cetuximab is a monoclonal antibody designed to interact with EGFR, block its activation …
Cetuximab is a monoclonal antibody designed to interact with EGFR, block its activation …
Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance
R Krumbach, J Schüler, M Hofmann… - European journal of …, 2011 - Elsevier
Cetuximab (Erbitux®) targets the epidermal growth factor receptor (EGFR) and is approved
for treatment of colorectal and head and neck cancer. Despite wide expression of EGFR …
for treatment of colorectal and head and neck cancer. Despite wide expression of EGFR …
The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy
H Zaryouh, I De Pauw, H Baysal, P Pauwels… - Frontiers in …, 2021 - frontiersin.org
The epidermal growth factor receptor (EGFR) is a therapeutic target in head and neck
squamous cell carcinoma (HNSCC). Resistance to EGFR-targeted therapies, such as …
squamous cell carcinoma (HNSCC). Resistance to EGFR-targeted therapies, such as …
Receptor tyrosine kinase plasticity as a mechanism of acquired resistance to cetuximab in vitro: potential for co-targeting with antibody mixtures.
I Kjaer, M Kragh, ID Horak, MW Pedersen - Cancer Research, 2013 - AACR
Cetuximab is an EGFR-blocking antibody that belongs to the first generation of monoclonal
antibodies approved for treatment of head and neck squamous cell carcinoma and …
antibodies approved for treatment of head and neck squamous cell carcinoma and …
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
DL Wheeler, S Huang, TJ Kruser, MM Nechrebecki… - Oncogene, 2008 - nature.com
The epidermal growth factor receptor (EGFR) is a central regulator of proliferation and
progression in human cancers. Five EGFR inhibitors, two monoclonal antibodies and three …
progression in human cancers. Five EGFR inhibitors, two monoclonal antibodies and three …
Abstract A146: Targeting AKT signaling overcomes acquired resistance to cetuximab in non-small lung cancer cells.
M Iida, DA Campbell, TM Brand, C Li… - Molecular Cancer …, 2011 - AACR
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in
human cancers. Cetuximab is an anti-EGFR antibody that has been approved by FDA for the …
human cancers. Cetuximab is an anti-EGFR antibody that has been approved by FDA for the …
[HTML][HTML] A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck …
EM Bahassi, YQ Li, TM Wise-Draper, L Deng… - European Journal of …, 2013 - Elsevier
BACKGROUND: Cetuximab is an epidermal growth factor receptor (EGFR)-blocking
antibody that has been approved for the treatment of patients with head and neck squamous …
antibody that has been approved for the treatment of patients with head and neck squamous …
Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab
DL Wheeler, M Iida, TJ Kruser… - Cancer biology & …, 2009 - Taylor & Francis
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that plays a major
role in oncogenesis. Cetuximab is an EGFR-blocking antibody that is FDA approved for use …
role in oncogenesis. Cetuximab is an EGFR-blocking antibody that is FDA approved for use …
Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency
Y Ohnishi, Y Minamino, K Kakudo… - Oncology …, 2014 - spandidos-publications.com
Cetuximab, a specific anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is
used in cancer treatment. Although development of resistance to cetuximab is well …
used in cancer treatment. Although development of resistance to cetuximab is well …